48.71 0.00 (0.00%)
After hours: 4:43PM EDT
|Bid||48.71 x 1000|
|Ask||53.65 x 900|
|Day's Range||48.63 - 50.84|
|52 Week Range||41.63 - 96.85|
|Beta (3Y Monthly)||2.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.63|
Agios Pharmaceuticals Inc NASDAQ/NGS:AGIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AGIO are favorable, with net inflows of $3.33 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, June 11, 2019 at 2:40 p.m. PT. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the planned retirement of its chief scientific officer, Scott Biller, Ph.D. Dr. Biller will retire from his CSO position at the end of 2019 and continue to serve as a strategic advisor through the end of 2020. Under his leadership, the team has built a robust preclinical pipeline and advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage clinical programs,” said Jackie Fouse, Ph.D., chief executive officer at Agios. “It has been a privilege and honor to be a part of the Agios team for nearly a decade and to work toward our shared vision of making a meaningful impact on the lives of patients,” said Dr. Biller.
– With Longer Follow Up, CR+CRh Rate Increased to 70% and CR Rate Increased to 61% in the Phase 1 Study of TIBSOVO® in Combination with Azacitidine – – Phase 1 Data of Single.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...
Although it is rapidly approaching 13F season and traders are closely watching oil stocks due to the rising Middle East tensions, several stocks such as Alibaba Group Holding Limited (NYSE:BABA), Altaba Inc. (NASDAQ:AABA), Cisco Systems, Inc. (NASDAQ:CSCO), Agios Pharmaceuticals Inc (NASDAQ:AGIO), and Virtusa Corporation (NASDAQ:VRTU) are in the spotlight for various reasons. Let's analyze why traders are watching each stock […]
Shares of Cisco Systems CSCO rose more than 2.5% in extended trading Wednesday after the networking hardware company reported better-than-expected fourth quarter results. The company also gave strong guidance for the fourth quarter with estimated earnings per share and revenue both coming in higher than Refinitiv consensus estimates. Farfetch reported a loss of 22 cents per share, worse than the expected loss of 16 cents per share, and revenue of $174.1 million, higher than the expected $171.1 million, according to Refinitiv consensus estimates.
CAMBRIDGE, Mass., May 15, 2019 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
– TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo – – Safety Profile Consistent with Published Phase 1 Data in.
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.
– TIBSOVO® is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy – – sNDA Approval Based.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.62% and 38.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?